Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma

20201,150 citationsJournal Articlehybrid Open Access

Authors

Lenvatinib plus pembrolizumab has promising antitumor activity in uHCC. Toxicities were manageable, with no unexpected safety signals.

Good health and well-being

Published in: Journal of Clinical Oncology

Volume 38, Issue 26, pp. 2960-2970

Field-Weighted Citation Impact: 97.97